All In Biotech

Drug Trial Radar · NCT00094302

Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function

Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT)

Last checked: Nov 19, 2026Latest source record: Mar 2, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,445 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,445

Actual

Start

Aug 2006

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Lead sponsor
Carelon ResearchAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Oct 15, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness of aldosterone antagonist therapy in reducing cardiovascular mortality, aborted cardiac arrest, and heart failure hospitalization in patients who have heart failure with preserved systolic function.

Conditions

  • Cardiovascular Diseases
  • Heart Diseases
  • Heart Failure, Congestive

Interventions

  • SpironolactoneDrug

    Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.

  • PlaceboDrug

    Placebo of spironolactone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite Outcome of Cardiovascular Mortality, Aborted Cardiac Arrest, or Hospitalization for the Management of Heart Failure, Whichever Occurred FirstTime frame: Randomization through each subject's last semi-annual visit, up to a maximum of 6 years per subject.

Locations

270 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Cardiovascular Consultants, Ltd.

    Glendale, Arizona

  • Carl T. Hayden VA Medical Center

    Phoenix, Arizona

  • Central Arkansas Veterans Healthcare System

    Little Rock, Arkansas

  • Heart Clinic Arkansas

    Little Rock, Arkansas

  • Cynthia Thaik

    Burbank, California

  • Fresno VA Medical Center

    Fresno, California

  • Clinica Medica San Miguel

    Los Angeles, California

  • CAPRI

    Los Angeles, California

  • VA Medical Center West Los Angeles

    Los Angeles, California

  • Mehrdad Kevin Ariani, MD, Inc.

    Northridge, California

  • UC Davis Medical Center

    Sacremento, California

  • Central Coast Cardiology

    Salinas, California

  • Naval Medical Center San Diego

    San Diego, California

  • Olive View - UCLA Medial Center

    Sylmar, California

  • University of Colorado Health Sciences Center

    Aurora, Colorado

  • Cardio-Vascular Institute

    Greeley, Colorado

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Washington Hospital Center

    Washington D.C., District of Columbia

  • Howard University Hospital

    Washington D.C., District of Columbia

  • Washington DC VA Hospital

    Washington D.C., District of Columbia

  • Daytona Heart Group

    Daytona Beach, Florida

  • M & O Clinical Research, LLC

    Fort Lauderdale, Florida

  • Florida Heart Center

    Ft. Pierce, Florida

  • University of Florida

    Gainesville, Florida

  • Mayo Clinic Florida

    Jacksonville, Florida

  • Brevard Cardiovascular Research Associates, Inc

    Rockledge, Florida

  • Tallahassee Research Institute

    Tallahassee, Florida

  • Emory University at Grady Health System

    Atlanta, Georgia

  • Morehouse School of Medicine

    Atlanta, Georgia

  • Northside Cardiology Center

    Atlanta, Georgia

  • InnovaMed Alliance

    Marietta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • University of Illinois at Chicago Medical Center

    Chicago, Illinois

  • Northwestern University

    Chicago, Illinois

  • Cardiovascular Research Foundation

    Elk Grove Village, Illinois

  • Heart, Lung and Vascular Institute

    Peoria, Illinois

  • HeartCare Midwest

    Peoria, Illinois

  • The Care Group, LLC

    Indianapolis, Indiana

  • Cardiovascular Research of Northwest Indiana, LLC

    Munster, Indiana

Showing 40 of 270 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.